Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 October 2020 | Story Leonie Bolleurs | Photo Supplied
Dr Jan Swanepoel believes that the agricultural sector must be assisted in every possible way to shift its focus from mere subsistence farming, as is still the case in many parts of the world, to sustaining the lives of millions of people on the planet.

17 October is marked as International Day for the Eradication of Poverty by the United Nations (UN). 

The University of the Free State (UFS) is involved in several initiatives aimed at empowering communities to create a sustainable livelihood for themselves in the long run.

One of these initiatives includes a project to build competitiveness for communal farmers by developing the wool value chain in the Free State. 

The UFS Centre for Sustainable Agriculture, Rural Development and Extension (CENSARDE) submitted a proposal to the Regional Universities Forum for Capacity Building in Agriculture (RUFORUM); their proposal was selected, and they were awarded a grant of US$300 000. 

Dr Jan Swanepoel, Senior Lecturer and Researcher at CENSARDE, says the world is moving from local and national markets towards a global system of trading. This means that neighbouring farmers working on small plots of land may be competing with large industrial farmers from another country in a single marketplace.

A drive to commercialise

He adds that in developing countries, there is increasing pressure on farmers to commercialise their operations. “In order to meet the drive for greater commercialisation, new skills must be developed to support farmers in becoming better entrepreneurs. Assistance towards infrastructure must be provided; and the needs of farmers, such as market access, must be identified and catered for.”

Dr Swanepoel points out that the agricultural sector must be assisted in every possible way to shift its focus from mere subsistence farming, as is still the case in many parts of the world, to sustaining the livelihoods of millions of people on the planet. 

“As the agricultural sector starts to realise this more fundamental role and responsibilities with regard to production, new strategies can be conceived towards the enhancement of the socio-economic status of all role players in the agricultural sector,” he says.

One of the industries that agriculture in South Africa can expand on, is the wool industry. 

“China is the biggest buyer of South African wool. During lockdown, no wool from South Africa was exported to China, causing the price of wool to drop significantly. Fortunately, the markets have opened up, the excess wool from Australia has been absorbed, and China is buying wool at full capacity now. Even though the price of wool is 30% below the price of last year, the markets are reacting positively, showing a steady increase. Wool buyers believe that this trend will continue due to international market demand exceeding the supply,” says Dr Swanepoel.

He also believes the creation of niche products from the wool will add to the existing value chain, creating more jobs and an opportunity for enlarging the export market.

Profitable and sustainable venture

CENCARDE is involved in an attempt to transform communal woolgrowers’ production from an underachieving enterprise to a profitable, sustainable, and renewable venture to enhance the livelihoods of communal wool producers. 

“In addition, with the extension of the value chain directly to consumers, job creation and development plays a vital role in supporting the South African National Treasury’s strategy,” adds Dr Swanepoel.

This project is thus built around the commercialisation of wool production in the communal areas of the Free State, by developing strategies to be implemented concurrently in order to attempt to manage the various challenges faced by these growers. 

As part of this project, a centralised infrastructure hub will be established on the UFS experimental farm to support wool production and processing. Woolgrowers, sheepshearers, and men and women from the community will also be equipped with the necessary skills and knowledge to operate in the wool industry. Adding to these skills, members of the community will be taught entrepreneurial skills in different aspects of wool processing, such as knitting, making felt products, spinning, and weaving. 

Another helpful aspect of this project is linking the communal woolgrowers to markets, and in so doing, giving them a collaborative advantage.

Educational benefits

However, not only communal woolgrowers will benefit from this programme. It also has educational benefits, as the project is designed to incorporate research. According to Dr Swanepoel, CENSARDE is very committed and are using this project as a pilot to demonstrate the potential for a more multidisciplinary, multi-stakeholder approach to education, research, and development. Fifteen students will directly benefit from this project, including two PhD and three master’s students.

Also adding value to the project is the development of private partnerships in the form of the Dohne Merino Breed Society, commercial farmers, and other key wool marketing agencies – which will assist with technical matters and knowledge – as well as the Free State Department of Agriculture.

All participants strive for more profitable and competitive communal woolgrowers in a changing global wool market. The project is not another educational exercise but will equip woolgrowers to change their circumstances for the better.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept